99 related articles for article (PubMed ID: 7769797)
21. Additive effects of combined angiotensin-converting enzyme inhibition and angiotensin II antagonism on blood pressure and renin release in sodium-depleted normotensives.
Azizi M; Chatellier G; Guyene TT; Murieta-Geoffroy D; Ménard J
Circulation; 1995 Aug; 92(4):825-34. PubMed ID: 7641363
[TBL] [Abstract][Full Text] [Related]
22. Inhibition of the acute effects of angiotensin II by the receptor antagonist irbesartan in normotensive men.
Ribstein J; Picard A; Armagnac C; Sissmann J; Mimran A
J Cardiovasc Pharmacol; 2001 Apr; 37(4):449-60. PubMed ID: 11300658
[TBL] [Abstract][Full Text] [Related]
23. Renin-angiotensin system and minoxidil-induced cardiac hypertrophy in rats.
Ruzicka M; Leenen FH
Am J Physiol; 1993 Nov; 265(5 Pt 2):H1551-6. PubMed ID: 8238566
[TBL] [Abstract][Full Text] [Related]
24. Effects of the angiotensin II receptor antagonist losartan on 24-hour blood pressure profiles of primary and secondary hypertensive rats.
Schnecko A; Witte K; Lemmer B
J Cardiovasc Pharmacol; 1995 Aug; 26(2):214-21. PubMed ID: 7475045
[TBL] [Abstract][Full Text] [Related]
25. Efficacy of SR 47436 (BMS-186295), a non-peptide angiotensin AT1 receptor antagonist in hypertensive rat models.
Lacour C; Canals F; Galindo G; Cazaubon C; Segondy D; Nisato D
Eur J Pharmacol; 1994 Nov; 264(3):307-16. PubMed ID: 7698170
[TBL] [Abstract][Full Text] [Related]
26. The effects of angiotensin II receptor blockade with losartan on systemic blood pressure and renal and extrarenal prostaglandin synthesis in women with essential hypertension.
Smith MC; Barrows S; Meibohm A; Shahinfar S; Simpson RL; Weigel K; Dunn MJ
Am J Hypertens; 1995 Dec; 8(12 Pt 1):1177-83. PubMed ID: 8998251
[TBL] [Abstract][Full Text] [Related]
27. Responses to low dose intravenous perindoprilat infusion in salt deplete/salt replete normotensive volunteers.
MacFadyen RJ; Lees KR; Reid JL
Br J Clin Pharmacol; 1994 Oct; 38(4):329-34. PubMed ID: 7833222
[TBL] [Abstract][Full Text] [Related]
28. Pharmacokinetics and biochemical efficacy after single and multiple oral administration of losartan, an orally active nonpeptide angiotensin II receptor antagonist, in humans.
Ohtawa M; Takayama F; Saitoh K; Yoshinaga T; Nakashima M
Br J Clin Pharmacol; 1993 Mar; 35(3):290-7. PubMed ID: 8471405
[TBL] [Abstract][Full Text] [Related]
29. Effect of enalapril (MK-421), an orally active angiotensin I converting enzyme inhibitor, on blood pressure, active and inactive plasma renin, urinary prostaglandin E2, and kallikrein excretion in conscious rats.
Schiffrin EL; Gutkowska J; Thibault G; Genest J
Can J Physiol Pharmacol; 1984 Jan; 62(1):116-23. PubMed ID: 6143602
[TBL] [Abstract][Full Text] [Related]
30. Angiotensinergic versus nonangiotensinergic hemodynamic effects of converting enzyme inhibition in patients with chronic heart failure. Assessment by acute renin and converting enzyme inhibition.
Kiowski W; Beermann J; Rickenbacher P; Haemmerli R; Thomas M; Burkart F; Meinertz T
Circulation; 1994 Dec; 90(6):2748-56. PubMed ID: 7994817
[TBL] [Abstract][Full Text] [Related]
31. Hemodynamic and humoral effects of the angiotensin II antagonist losartan in essential hypertension.
Grossman E; Peleg E; Carroll J; Shamiss A; Rosenthal T
Am J Hypertens; 1994 Dec; 7(12):1041-4. PubMed ID: 7702796
[TBL] [Abstract][Full Text] [Related]
32. Multiple dose pharmacokinetics and concentration effect relationship of the orally active renin inhibitor remikiren (Ro 42-5892) in hypertensive patients.
Weber C; Birnböck H; Leube J; Kobrin I; Kleinbloesem CH; Van Brummelen P
Br J Clin Pharmacol; 1993 Dec; 36(6):547-54. PubMed ID: 12959271
[TBL] [Abstract][Full Text] [Related]
33. Renal and systemic effects of continued treatment with renin inhibitor remikiren in hypertensive patients with normal and impaired renal function.
van Paassen P; de Zeeuw D; Navis G; de Jong PE
Nephrol Dial Transplant; 2000 May; 15(5):637-43. PubMed ID: 10809804
[TBL] [Abstract][Full Text] [Related]
34. Juxtaglomerular cell hypertrophy and hyperplasia induced in rhesus monkeys by angiotensin II receptor antagonists.
Owen RA; Molon-Noblot S; Hubert MF; Siegl PK; Eydelloth RS; Keenan KP
Lab Invest; 1994 Oct; 71(4):543-51. PubMed ID: 7967510
[TBL] [Abstract][Full Text] [Related]
35. Losartan reduces albuminuria in patients with essential hypertension. An enalapril controlled 3 months study.
Nielsen S; Dollerup J; Nielsen B; Jensen HA; Mogensen CE
Nephrol Dial Transplant; 1997; 12 Suppl 2():19-23. PubMed ID: 9269694
[TBL] [Abstract][Full Text] [Related]
36. Effects of losartan on the renin-angiotensin-aldosterone axis in essential hypertension.
Bauer IH; Reams GP; Wu Z; Lau-Sieckman A
J Hum Hypertens; 1995 Apr; 9(4):237-43. PubMed ID: 7595905
[TBL] [Abstract][Full Text] [Related]
37. Effect of losartan and enalapril on renal adaptation sodium restriction in rat.
Jover B; Saladini D; Nafrialdi N; Dupont M; Mimran A
Am J Physiol; 1994 Aug; 267(2 Pt 2):F281-8. PubMed ID: 8067389
[TBL] [Abstract][Full Text] [Related]
38. Endogenous angiotensin II and baroreceptor dysfunction: a comparative study of losartan and enalapril in man.
Yee KM; Struthers AD
Br J Clin Pharmacol; 1998 Dec; 46(6):583-8. PubMed ID: 9862248
[TBL] [Abstract][Full Text] [Related]
39. Efficacy and safety of losartan.
Goldberg A; Sweet C
Can J Cardiol; 1995 Aug; 11 Suppl F():27F-32F. PubMed ID: 7664215
[TBL] [Abstract][Full Text] [Related]
40. Effect of ANG II receptor antagonist on albuminuria and renal function in passive Heymann nephritis.
Hutchinson FN; Webster SK
Am J Physiol; 1992 Aug; 263(2 Pt 2):F311-8. PubMed ID: 1510124
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
